NONOF - Employer coverage for GLP-1s rising amid FDA label expansions: survey
2024-06-14 08:01:46 ET
More on Eli Lilly, Novo Nordisk, etc.
- Eli Lilly: The Road To Approval Of Donanemab Is Open
- Eli Lilly and Company (LLY) Goldman Sachs 45th Annual Global Healthcare Conference
- Is It Possible Eli Lilly Is Breaking Out To New All-Time Highs?
- Lilly's Retevmo gains traditional approval in thyroid cancer
- GLP-1 obesity drug coverage dropped by Blue Cross Michigan: report